FIELD: pharmaceuticals.
SUBSTANCE: invention relates to peptide analogues of dolaproin-dolaizolein, pharmaceutical compositions containing such compounds, and methods for treatment of malignant neoplasms using such compounds.
EFFECT: obtaining one more compound to treat malignant neoplasms.
22 cl, 30 dwg, 64 ex
| Title | Year | Author | Number |
|---|---|---|---|
| DERIVATIVES OF DOLASTATIN 10 AND AURISTATINS | 2014 |
|
RU2662951C2 |
| ANTIBODY-DRUG CONJUGATES (ADC) WHICH BIND TO FLT3 PROTEINS | 2016 |
|
RU2739617C2 |
| LIGAND CONJUGATE WITH CYTOTOXIC DRUG PREPARATION, METHOD AND APPLICATION THEREOF | 2016 |
|
RU2708461C2 |
| CONJUGATE OF ANTI-IGF-1R ANTIBODY WITH DRUG AND USE THEREOF FOR TREATING CANCER | 2015 |
|
RU2692563C2 |
| CYTOTOXIC AND ANTIMITOTIC COMPOUNDS AND METHODS OF USING THEM | 2015 |
|
RU2723651C2 |
| CYTOTOXIC PEPTIDES AND ANTIBODY-DRUG CONJUGATES THEREOF | 2012 |
|
RU2586885C2 |
| ANTIBODY AND MEDICINAL AGENT CONJUGATE AND USE THEREOF FOR TREATING CANCER | 2015 |
|
RU2685259C2 |
| CONJUGATES OF MONOMETHYL AURISTATIN E WITH ASIALOGLYCOPROTEIN RECEPTOR LIGANDS FOR TARGETED TRANSPORT INTO TUMOR CELLS OF LIVER | 2022 |
|
RU2809635C1 |
| DERIVATIVES OF DOLASTATIN 10 | 2002 |
|
RU2296750C2 |
| NEW CONJUGATES BINDING COMPOUND - ACTIVE COMPOUND (ADC) AND USE THEREOF | 2012 |
|
RU2610336C2 |
